Treatment success in patients requiring treatment change from olanzapine to risperidone long acting injectable (TRESOR)
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2012
At a glance
- Drugs Risperidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms TRESOR
- Sponsors Janssen Pharmaceutica
- 27 Apr 2010 Actual number of patients (99) added as reported by ClinicalTrials.gov record.
- 27 Apr 2010 Actual end date (1 Jul 2007) added as reported by ClinicalTrials.gov record.
- 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.